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After completing this course, the reader will be able to:
1. Discuss the current literature on the neoadjuvant therapies in patients with potentially resectable and borderline
resectable pancreatic cancer.
2. Cite the definition of borderline resectable pancreatic cancer as determined by the 2008 AHPBA consensus
guidelines.
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ABSTRACT
Pancreatic cancer remains one of the deadliest cancers due to
difficulty in early diagnosis and its high resistance to chemo-
therapy and radiation. It is now clear that even patients with
potentially resectable disease require multimodality treat-
ment including chemotherapy and/or radiation to improve
resectability and reduce recurrence. Tremendous efforts are
currently being invested in refining preoperative staging to
identify optimal surgical candidates, and also in developing
various neoadjuvant or adjuvant regimens to improve surgi-
cal outcome. Although at present no studies have been done to
directly compare the benefit of neoadjuvant versus adjuvant
approaches, accumulating evidence suggests that the neoad-
juvant approach is probably beneficial for a subset of the pa-
tient population, particularly those with borderline resectable
disease in which complete surgical resection is almost cer-
tainly unachievable. In this article, we review the literature
and rationales of neoadjuvant chemotherapy and chemora-
diation, as well as their potential limitations and caveats. We
also review the pathological findings following neoadjuvant
therapies, and potential surgical complications that may be
associated with neoadjuvant therapies. The Oncologist 2012;
17:192–200
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INTRODUCTION
Pancreatic cancer is the fourth most common cancer-related
death in men and women in the United States. The 5-year sur-
vival rate for patients with pancreatic cancer remains 5% [1].
To date, the only chance for cure exists for patients with local
disease undergoing surgical resection of the primary tumor and
regional lymph nodes. Unfortunately, only 15%–20% of pa-
tients with pancreatic cancer are deemed resectable at the time
of presentation, and the majority of those who receive curative
surgical resection will eventually succumb to locoregional re-
currence or distant metastasis [2, 3].
At least two major factors contribute to the poor outcome after
surgical resection of pancreatic cancer: (a) the inability of current
radiographic techniques to distinguish patients with truly local-
ized disease from those with micrometastasis prior to surgery and
(b) the lack of therapeutic agents that are effective against micro-
metastatic disease. In fact, studies have shown that the length of
survival for patients with an incomplete resection is no different
from that of patients with locally advanced, surgically unresect-
able disease treated with chemoradiation. Increasing attention is
now focused on neoadjuvant chemotherapy and/or radiation to
improve resectability and long-term survival. This article de-
scribes the rationales of neoadjuvant approaches and reviews im-
portant clinical trials of neoadjuvant therapies in patients with
resectable pancreatic cancer. The pathologic findings after neoad-
juvant therapy and the surgical concerns associated with the neo-
adjuvant approach are also discussed.
RATIONALES FOR NEOADJUVANT THERAPY
The rationale of neoadjuvant therapy was born out of the ad-
juvant approach to cancer therapy. Over the last few years,
three large randomized phase III trials in pancreatic cancer
have reported the benefit of adjuvant therapy either with che-
motherapy or chemoradiation. In the Charite Onkologie Clin-
ical Studies in GI Cancer (CONKO)-001 trial, 368 patients
after R0 or R1 surgical resection were randomized to strict ob-
servation or administration of six cycles of gemcitabine [4].
During a median follow-up of 53 months, patients in the gem-
citabine arm were found to have superior median disease-free
survival (DFS) compared with the observation arm (13.4
months versus 6.9 months; p  .001), but the median overall
survival (OS) between the two groups was not different (22.1
months with gemcitabine versus 20.2 months of observation,
p  .06). The authors attributed the lack of difference in me-
dian OS to the fact that almost all patients in the observation
arm received gemcitabine or other chemotherapy upon relapse.
The final results of the CONKO-001 trial were presented at the
American Society of Clinical Oncology annual meeting in
2008. By intention-to-treat analysis, patients who received ad-
juvant gemcitabine for 6 months (n  179) had superior DFS
(13.4 months versus 6.9 months, p  .001), median survival
(22.8 months versus 20.2 months, p  .006), 3-year survival
(36.5% versus 19.5%), and 5-year survival (21% versus 9%)
compared to patients in the observation arm (n  175) [5].
These results support the role of gemcitabine as adjuvant ther-
apy in pancreatic cancer.
In a prospective randomized trial conducted by the Radia-
tion Therapy Oncology Group-9704, 451 patients underwent
surgical resection, but importantly, those without radiographic
evidence of persistent disease or relapse were randomized to
receive either adjuvant infusional fluorouracil or gemcitabine
for 3 weeks followed by fluorouracil-based chemoradiation an
additional 12 weeks after chemoradiation. No statistically sig-
nificant difference in survival was observed between the two
arms (gemcitabine versus fluorouracil; median survival 20.5
months versus 16.9 months; p  .9) [6].
Lastly, in the European Study Group for Pancreatic Cancer
(ESPAC)-3 trial, 1,088 patients who underwent pancreatic re-
section were randomized to receive either adjuvant fluoroura-
cil plus folinic acid (n  551) or gemcitabine (n  537) for six
cycles. At the 2-year follow-up, adjuvant gemcitabine or fluo-
rouracil plus folinic acid showed similar median OS (23.6
months versus 23.0 months, p  .39) and median progression-
free survival (14.3 months versus 14.1 months), although gem-
citabine was associated with significantly less adverse side
effects [7]. The ESPAC-3 trial suggested that fluorouracil plus
folinic acid can be used as an alternative to gemcitabine in the
adjuvant setting.
In patients who completed surgical resection and adju-
vant chemotherapy and/or radiation, the risk for systemic
recurrence can be as high as 77% [6]. Furthermore, the sur-
vival outcomes in these three studies are similar, reflecting
the fact that the benefit of the adjuvant approach, at least
based on these regimens, might have reached a plateau. Un-
questionably, various other combinations of chemothera-
peutic and targeted agents are currently being investigated
and could potentially improve surgical outcomes in the fu-
ture. In parallel, several rationales have been proposed to
advocate use of chemotherapy and/or chemoradiation be-
fore curative resection:
(a) The initiation of adjuvant therapy is frequently delayed
due to inadequate recovery from surgery, especially in patients
receiving the Whipple procedure to resect a tumor in the head
of pancreas. Such a delay can be easily avoided by administer-
ing therapies before surgery. Additionally, the chance of de-
livering full-dose chemotherapy and/or radiation is much
higher when given prior to surgery. For instance, 90%–100%
of patients were able to complete all planned neoadjuvant gem-
citabine-based regimens prior to surgery [8–10], as opposed to
only 62% of patients in the CONKO-001 trial who received
adjuvant gemcitabine as planned due to poor wound healing or
other postoperative complications [4].
(b) Neoadjuvant therapies provide a window to spare pa-
tients who progress or develop distant metastasis during treat-
ment from undergoing a major surgery which would not be
curative anyway.
(c) Neoadjuvant therapies could potentially downstage
borderline resectable disease and enhance the rate of R0 resec-
tion.
NEOADJUVANT RADIATION
The neoadjuvant approach has been validated in other tumor
types, and it was initially evaluated in pancreatic cancer three
decades ago. In the 1980s, Ishikawa et al. reported a retrospec-
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tive study comparing 23 patients with radiographically resect-
able pancreatic cancer who received neoadjuvant radiotherapy
(totally 50 Gy) and 31 patients who only underwent resection.
The curative pancreaticoduodenectomy rate was similar for
both groups (74% versus 61%). However, patients who re-
ceived preoperative radiation had a better one-year survival
rate (75% versus 43%), primarily due to lower locoregional re-
currence, but a similar 3- to 5-year survival rate (8% versus
32% and 22% versus 26%, respectively) due to the higher in-
cidence of liver metastases [11]. Despite several limitations, a
retrospective analysis of the surveillance, epidemiology, and
end results (SEER) database from 1988 to 2003 showed a sur-
vival benefit in patients who received radiation before surgery
[12].
NEOADJUVANT CHEMOTHERAPY
AND CHEMORADIATION
Evidence to support neoadjuvant chemoradiation was estab-
lished from several phase II trials conducted in the past two
decades. The series of studies with perhaps the most impact
were from the MD Anderson Cancer Center (MDACC) (Table
1). In the six published phase II trials, the definition of “resect-
able” tumors was defined and remained constant, as have the
operative techniques employed. This series of trials provides a
unique framework to understand the context and incremental
changes of each successive trial. Overall, these studies showed
that patients who completed neoadjuvant chemoradiation and
did not progress at restaging had a higher chance of achieving
R0 resection when compared to historical data. Importantly,
this was translated into a higher median and overall survival
compared to patients who did not receive surgical resection.
However, a note should be made about the large number of
vascular resections performed at MDACC. In a review of 132
consecutively treated patients with neoadjuvant chemoradia-
tion, 43% required a vascular resection and reconstruction at
the time of pancreaticoduodenectomy [13]. The authors ac-
knowledge that what may be considered “resectable” at
MDACC might not be considered resectable in many other
centers.
Although combined chemoradiation has been shown to im-
prove local control, it does not effectively decrease distant me-
tastasis, and this could be due to patients having a lower
tolerance for cytotoxic agents when also receiving radiation.
Accordingly, neoadjuvant chemotherapy alone may allow de-
livery of higher doses of cytotoxic agents, which could theo-
retically lead to more effective elimination of distant
micrometastasis and potentially improve long-term outcome.
To date, no comparison has been done between neoadjuvant
chemotherapy versus combined chemoradiation. Several other
studies by various institutions have also shown improved re-
sectability and survival with neoadjuvant chemotherapy with
or without radiation (Table 2).
At least two caveats must be acknowledged while inter-
preting data from these neoadjuvant trials. First, the definition
of resectability used in most literature is inconsistent and often
difficult to interpret, which leads to difficulty in comparing re-
sults from different trials. Additionally, what may be consid-
ered “resectable” with a venous resection in one institution
may be considered “borderline” resectable or even unresect-
able in another. A second caveat is that our ability to correctly
stage pancreatic cancer has changed over time, which has led
to potential stage migration. In a number of earlier trials, one
method for obtaining a tissue diagnosis and determining re-
sectability included an exploratory laparotomy [14, 15]. Over
time, diagnostic and staging laparotomies have decreased, and
the utilization of endoscopic ultrasounds and computer tomog-
raphy scans (CTs) has increased. With improved CTs, mag-
netic resonance imaging scans, and positron emission
tomography (PET)-CTs, investigators are more equipped to
determine whether a tumor is resectable, locally advanced, or
even metastatic. Any survival benefit seen with improved
treatment regimens and newer chemotherapies may simply be
a result of stage migration. For instance, even within the
MDACC phase II trials, the trend toward improvement in me-
dian survival over time might be a result of better selection of
patients.
SURGICAL DEFINITION OF RESECTABLE, BORDERLINE
RESECTABLE, AND LOCALLY ADVANCED DISEASE
Multidetector CT with three-dimensional (3-D) reconstruction
is currently the modality of choice to preoperatively stage pan-
creatic cancer. Preoperative CTs for pancreatic cancer have
been shown to have a high predictive value for unresectability
(90%–100%) with a slightly lower predictive value of resect-
ability (76%–90%). A thorough radiographic assessment in-
cludes noting the presence or absence of distant metastatic
disease and the relationship of the tumor to superior mesenteric
vein and portal vein and their tributaries, superior mesenteric
artery, celiac axis, hepatic artery, and gastroduodenal artery.
On the basis of the radiographic findings, pancreatic cancers
are classified as resectable, borderline resectable, or unre-
sectable (locally advanced or metastatic). However, the am-
biguity of these terms has generated a lot of controversy in
recent years, and it is likely that undefined discrepancies ex-
ist between trials reported in the literature, making it diffi-
cult to compare data between trials. In January of 2008, the
American Hepato-Pancreato-Biliary Association (AHPBA)
convened a Consensus Conference on Resectable and Border-
line Resectable Pancreatic cancer with the goal of clearly de-
fining resectable and borderline resectable pancreatic cancer
and reviewing the indications and contraindications for sur-
gery, neoadjuvant therapy, and adjuvant therapy for these le-
sions (Table 3) [16].
Up to one third of the patients with apparent resectable pan-
creatic cancer are found to have metastatic disease at the time
of operation. This is attributed to the low sensitivity of CTs to
visualize small-volume metastatic disease. This has led sur-
geons to perform laparoscopy as part of preoperative staging in
selected patients with the goal of avoiding the morbidity asso-
ciated with an unnecessary laparotomy. A number of predic-
tors have been identified that optimize the yield of performing
a staging laparoscopy for apparently resectable pancreatic can-
cer: (a) tumors 3 cm at the head of the pancreas; (b) tumors of
the pancreatic body and tail; (c) equivocal findings of resect-
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ability based on the above-mentioned parameters on CTs; and
(d) CA19–9 levels 100 U/mL. A staging laparoscopy may
also be used in patients with locally advanced unresectable
pancreatic cancer to rule out undetected metastatic disease to
optimize treatment selection.
NEOADJUVANT THERAPY FOR BORDERLINE
RESECTABLE PANCREATIC CANCER
First defined by Varadhachary et al. in 2006 and later adopted
in the National Comprehensive Cancer Network (NCCN)
guidelines in 2008, borderline resectable pancreatic cancer
represents a distinct disease subset defined by CT findings that
straddle the definitions of resectable and locally advanced dis-
ease [17, 18]. Patients with borderline resectable disease pose
a therapeutic dilemma because of their low chance of R0 re-
section if immediate surgery is preferred but otherwise bleak
chance of cure with nonsurgical therapies. One often-cited ad-
vantage of neoadjuvant therapy has been the potential to down-
stage patients with borderline resectable pancreatic cancer and
thereby increases their chance for R0 resections. The veracity
Table 1. MD Anderson phase II trials
Study Date Pts Chemotherapy Radiotherapy
Taken to
surgery
All pts
resected
Vessel
resection
Median survival
All/R/UR
Overall survival
All/R/UR
Local
recurrence
after
resection
Distant
metastasis
after
resection
Liver
metastatis
after
resection
R0
resection
Node

88-004
39
1992 28 5-FU 300 mg/m2 5 d/wk
CI
50.4
Gy  IORT
(10–20 Gy)
82% 35% 24% 83% 29%
93-007
40
1998 35 5-FU 300 mg/m2 5 d/wk
CI
30 Gy  IORT
(10–15 Gy)
77% 57% 50% —/25 mo(s)/7 mo(s) —/23%/0% (3 yr(s)) 5% 65% 50% 90% 65%
95-224
41
2002 37 Paclitaxel 60 mg/m2
weekly 3
30 Gy  IORT
(10–15 Gy)
71% 57% 35% 12 mo(s)/19 mo(s)/10 mo(s) 14%/28%/0% (3 yr(s)) 0% 84% 79% 68% 53%
98-020
27
2008 86 Gem 400 mg/m2
weekly 7
30 Gy 85% 74% 20% 22.7 mo(s)/34 mo(s)/7.1 mo(s) 27%/36%/0% (5 yr(s)) 11%a 59%a 23% 89% 38%
01-341
26
2008 90 Gem 750 mg/m2 and Cis
30 mg/m2 every 2
wk(s) 4, and then Gem
400 mg/m2 during
radiotherapy
30 Gy 69% 66% 37% 17.4 mo(s)/31 mo(s)/10.5 mo(s) 25%a 73%a 96% 58%
aFirst site of failure.
Abbreviations: 5-FU, 5-fluorouracil; All/R/UR, all/resected/unresected; CI, continuous infusion; Cis, cisplatin; d, day(s);
Gem, gemcitabine; Gy, gray; IORT, intraoperative radiotherapy; mo(s), month(s); Pts, patients; wk(s), week(s); yr(s),
year(s).
Table 2. Other major neoadjuvant trials
Study Institution Date Pts Chemotherapy RT Resectability
% Taken
to surgery
% All
pts
resected
Median survival
All/R/UR
Overall survival
All/R/UR
Local
recurrence
after
resection
Distant
metastasis
after
resection
Liver
metastatis
after
resection
R0
resections
Hoffman
et al. 42
Fox Chase 1995 34 5-FU 1 g/m2/d 4 days d2–5
and d29–32; Mitomycin C 10
mg/m2 d2
50.4 Gy resectable/
unresectable
76% 33% —/45 mo(s)/— —/40%/— 9% 45% 45% 91%
Hoffman
et al. 43
ECOG 1998 53 5-FU 1 g/m2/d 4 days d2–5
and d29–32; Mitomycin C 10
mg/m2 d2
50.4 Gy resectable/
borderline
77% 45% 10.9 mo(s)/15.7 mo(s)/— —/27%/— (2 yr(s)) 13% 79% 50% 67%
Magnin
et al. 44
French 2003 32 5-FU 650 mg/m2 CI d1–5 and
d21–25 with Cis bolus 80 mg/
d/m2 d2 and d22
15 Gy x2 split
course; or 45 Gy
resectable/
borderline
59% 16 mo(s)/30 mo(s)/— 37%/59%/—
(2 yr(s))
Ohigashi
et al. 45
Japanese 2005 19 5-FU 3 g/12 days preop;
postop 5-FU 125 mg/d direct
CI 28 days; 5-FU 500 mg/d
for 3 days with RT 2 cycles
Split course 24 Gy
preop, 36 Gy
postop
resectable/
borderline
89% 79% —/62 mo(s)/— —/53%/— (3 yr(s)) 13% 27% 7% 80%
SFRO-FFCD
97-04
46
French
Cooperative
2006 41 5-FU 300 mg/m2 CI 5 d/wk
d1–5 and
d29–33; Cis 20 mg/m2 bolus
d1–5 and d29–33
50 Gy resectable/
borderline
89% 63% 9.5 mo(s)/11.7 mo(s)/— 20%/32%/0%
(2 yr(s))
4% 58% 31% 80%
Talamonti
et al. 47
US Multi
Institutional
2006 20 Gem 1000 mg/m2 d1 and
d8 3 cycles; cycle 2 d1, d8,
and d15 with RT
36 Gy resectable/
borderline
100% 85% —/26 mo(s)/— —/61%/—(2 yr(s)) 12% 47% 94% (all
pts)
Ohigashi
et al. 8
Japanese 2009 38 Gem 1000 mg/m2/wk 3/4
wk(s) 3 cycles; adjuvant
5-FU 125 mg/d 28 days
direct CI
50 Gy resectable/
borderline
91% 82% 32 mo(s)/—/13 mo(s) 41%/53%/0%
(5 yr(s))
6% 32% 13% 97%
Palmer
et al. 9
United
Kingdom
2007 Arm A:
24
Gem 1000 mg/m2/wk 6
cycles
resectable/
borderline
96% 38% 13.6 mo(s)/28.4 mo(s)/
8.6 mo(s)
52%/77.8%/22.2%
(1 yr)
Arm B:
26
Gem 1000 mg/m2  Cis 50
mg/m2 every week
85% 70%
Heinrich
et al. 10
Switzerland 2008 28 Gem 1000 mg/m2  Cis 50
mg/m2 every 2 wk(s) 4
cycles
resectable 93% 80% —/19.1 mo(s)/— 46% 46% 21%
Abbreviations: 5-FU, 5-fluorouracil; All/R/UR, all/resected/unresected; CI, continuous infusion; Cis, cisplatin; d, day(s);
ECOG, Eastern Cooperative Oncology Group; Gem, gemcitabine; Gy, gray; mo(s), month(s); Pts, patients; RT,
radiotherapy; SFRO-FFCD, Socie´te´ Française de Radiothérapie Oncologie and Fondation Francophone de Cancérologie
Digestive; wk(s), week(s); yr(s), year(s).
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of this claim is difficult to ascertain given the inconsistent in-
clusion of patients with both resectable and borderline resect-
able tumors in published clinical trials. A review of the
prospective neoadjuvant trials for resectable pancreatic can-
cers is summarized in Table 4.
The percentage of patients in these five trials with border-
line resectable cancers who underwent surgical resection
ranged from 33%–64%. Although only three of the five trials
specified vessel resection, the rate of resection was high, up to
64% [19]. More interestingly, the rate of R0 resections was
high in all studies, 87%–100%. Although small in number,
there appears to be good potential for downstaging of border-
line resectable tumors to achieve R0 resection.
The benefit of neoadjuvant therapies in borderline resect-
able pancreatic cancer was retrospectively reviewed by Katz et
al. at MDACC [20]. Between 1999 and 2006, 160 (7%) of
2,454 pancreatic cancer patients with borderline resectable dis-
ease were scheduled to receive 2– 4 months of neoadjuvant
chemotherapy followed by radiation in combination with
5-fluorouracil (5-FU), gemcitabine, capecitabine, or pacli-
taxel. Restaging CT was done every 2 months during the treat-
ment and 4 – 6 weeks after completion to determine
respectability. Patients who progressed or had declined perfor-
mance status during this period of treatment were excluded
from surgery. One-hundred twenty-five (78%) patients com-
pleted the restaging, 79 (63% of 125) patients proceeded to
surgery, and 66 (53% of 125) patients received pancreati-
coduodenectomy. Of all 160 patients with borderline resect-
able disease, the median survival was 18 months and the 5-year
survival was 18%. Importantly, the 66 patients who completed
all therapy including surgery had a superior median survival of
40 months and a 5-year survival rate of 36%, compared to a
median survival of 13 months in the remaining 94 unresected
patients. Patients with greater pathologic response or drop in
serum CA19–9 levels during neoadjuvant therapy had better
OS. However, 59% of the resected patients eventually had a
recurrence, and 45% of patients had recurrence occurring in
distant organs such as lung, liver, or bone, 9% had recurrence
in the pancreatic bed, and 11% had recurrence in the perito-
neum or regional lymph nodes. The median time to progres-
sion was 24 months, indicating a need to improve the efficacy
of neoadjuvant therapy.
SURGICAL COMPLICATIONS OF
PANCREATODUODENECTOMY AFTER
NEOADJUVANT THERAPY
Pancreatoduodenectomy is associated with a high morbidity
(30%–60%). The biggest concern with neoadjuvant therapy
for pancreatic cancer is its risk to increase perioperative mor-
bidity. It has been hypothesized that the detrimental effects of
neoadjuvant therapy on wound healing place patients at a
higher risk for complications like wound infections, anasto-
motic leaks, intra-abdominal abscesses, and death. However,
this association has yet to be seen in clinical studies.
Varadhachary et al. in 2008 conducted a phase II trial of
preoperative gemcitabine and cisplatin chemotherapy in addi-
tion to chemoradiation (gemcitabine, cisplatin, and radiation)
followed by pancreatoduodenectomy for adenocarcinoma of
the pancreatic head. Of the 90 patients enrolled, 52 underwent
pancreatoduodenectomy. There were no perioperative deaths,
and 5 (9.6%) patients developed a major complication, includ-
ing intraoperative cardiac arrest with successful resuscitation
(n  1), reoperation for a wound hematoma (n  1), aspiration
pneumonia and sepsis from central venous catheter infection
(n  1), and a biliary anastomotic leak (n  1). There were no
clinically significant pancreatic leaks. Evans et al. in 2008 sim-
ilarly reported a major complication rate of 9% in his review of
64 patients (of 86 enrolled) who underwent pancreatoduode-
Table 3. Resectable, borderline resectable, and unresectable pancreatic cancer as defined by the 2008 AHPBA/SSO/SSAT
consensus guidelines
Resectable Borderline Unresectable
SMV and portal vein Uninvolved with tumor with
clear fat planes around
vessels
Abutment, encasement, or occlusion
of short segment of vein
Occlusion, thrombosis,
or encasement
extending several
centimeters
SMA Uninvolved with tumor with
clear fat planes around
artery
Tumor abutment 180 degrees Tumor abutment 180
degrees (encasement)
or thrombosis of artery
Celiac axis Uninvolved Uninvolved celiac axis; short
segment encasement or abutment of
common hepatic artery may be
amenable to resection and
reconstruction
Abutment or
encasement of celiac
axis indicates
unresectability
Involved lymph nodes
outside area of
resection or presence
of distant metastases
No No Indicates
unresectability
Abbreviations: AHPBA, American Hepato-Pancreato-Biliary Association; SMA, superior mesenteric artery; SMV, superior
mesenteric vein; SSAT, Society for Surgery of the Alimentary Tract; SSO, Society of Surgical Oncology.
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nectomy after preoperative gemcitabine-based chemoradia-
tion. Complications included pancreatic leak (n  1), intra-
abdominal sterile fluid collections requiring percutaneous
drainage (n  2), biliary leak (n  1), postoperative GI bleed
(n  1), and chylous ascites (n  1) (Table 5). The morbidity
and mortality rates described in these studies are similar to
those reported after conventional pancreatoduodenectomy for
pancreatic cancer in high-volume centers and suggest that sur-
gery after neoadjuvant chemotherapy is safe.
PATHOLOGIC ASSESSMENT FOLLOWING
NEOADJUVANT THERAPY
In the literature, there are only a few studies on the pathologic
changes of pancreatic ductal adenocarcinoma with neoadju-
vant treatment. A recent report from the MDACC showed that
post-treatment pathologic American Joint Committee on Can-
cer (AJCC) stage and lymph node status following neoadju-
vant therapy are independent prognostic factors for both
disease-free survival and overall survival, whereas tumor
grade and margin status are independent factors for disease-
free survival for overall survival [21].
Cytologic changes associated with neoadjuvant treatment
include cytoplasmic swelling, vacuolization, clearing and eo-
sinophilia, nuclear enlargement, multiple nuclei, bizarre nu-
clear shape, hyperchromasia, pyknosis, and karyorrhexis.
Viable tumor cells are those with fairly preserved morphology
including those with nuclear or cytoplasmic swelling, multiple
nuclei, or cytoplasmic vacuolization. Nonviable tumor cells
are those with bizarre, hyperchromatic, pyknotic, or karyorrhe-
xic nuclei, usually with associated markedly swollen, vacuo-
lated, or deeply eosinophilic cytoplasm. Chemoradiation
typically induces stromal fibrosis both within the tumor and
the surrounding parenchyma, rendering accurate gross mea-
surement of the tumor size difficult. The mean fibrosis level
(defined as percentage of tumor area occupied by fibrosis) in
resection specimen was 73% in 61 patients who received neo-
adjuvant treatment, significantly higher than 38% in 55 pa-
tients who did not receive such treatment (p  .0001)
(unpublished data).
LIMITATIONS OF CURRENT NEOADJUVANT THERAPIES
To date, well-designed, randomized studies that directly com-
pare neoadjuvant therapy followed by resection to upfront re-
section, or comparison of the neoadjuvant approach versus the
adjuvant approach, are not available. Recently, a large meta-
analysis that included 111 studies and 4,394 patients found no
difference in resection rate or median survival between pa-
tients with initially resectable disease who were treated with
either the neoadjuvant or adjuvant approach [22]. The study
showed that about one third of patients with unresectable dis-
ease at diagnosis were able to undergo successful resection af-
ter neoadjuvant therapy, particularly with combination
regimens. Moreover, median survival following resection was
comparable to patients with resectable disease [22], which was
also consistent with another smaller meta-analysis [23], sup-
porting the ability of neoadjuvant therapy to downstage pan-
creatic cancer in a subset of patients. Because patients with
resectable disease appear to have similar outcomes when
treated with the neoadjuvant or adjuvant approach in general,
selection of either approach must be individualized and de-
cided by a multidisciplinary team. Upfront surgery should be
considered for patients with (a) gastric outlet obstruction, (b)
obstructive jaundice that fails to be relieved with a biliary stent,
(c) specimens for which a clear diagnosis cannot be made, (d)
relatively good preoperative performance status, and (e) ex-
pected satisfactory recovery from surgery, which would likely
allow adjuvant therapy to be given in time and at the full dose.
Patient preference after detailed discussion with the medical
oncologist and surgeon should also be a considerable factor in
the final decision making.
Currently, a multicenter, prospective randomized phase II
study has been launched to compare primary resection versus
neoadjuvant chemoradiation with cisplatin and gemcitabine
followed by resection for locally resectable or potentially re-
sectable pancreatic cancer [24]. Another phase III study
(NEOPAC) attempts to address whether addition of neoadju-
vant oxaliplatin plus gemcitabine will improve progression-
free survival in patients with resectable pancreatic cancer who
also receive adjuvant gemcitabine [25]. Importantly, the lack
Table 4. Neoadjuvant trials on borderline resectable pancreatic cancer
Study Date Pts Resectability Chemotherapy Radiotherapy Pts resected
Vessel
reconstruction
Median survival
All/R/UR
Overall survival
All/R/UR
R0
resection
Mehta
et al. 48
2001 15 Borderline 5-FU 250 mg/m2/d PVI 50.4–56 Gy 60% —/30 mo(s)/8
mo(s)
100%
Massucco
et al. 49
2006 28 18 Borderline,
10 unresectable
(1) Gem 50–100 mg/m2 2 per
week for 5 wk(s); (2) Gem 
oxaliplatin
45 Gy 39% of
borderline
38% 15.4 mo(s)/21
mo(s)/10 mo(s)
15.4%/52.5%/0%
(2 yr(s), all pts)
87%
(all pts)
Small
et al. 50
2008 39 16 Resectable,
9 borderline, 14
unresectable
Gem 1000 mg/m2 d1 and d8 3
cycles; during cycle 2 Gem d1, d8,
and d15 with radiotherapy
36 Gy in 2.4 Gy/fx 33% of
borderline
76% borderline
(1 yr)
94%
(all pts)
Patel
et al. 19
2011 17 Borderline Gem 750 mg/m2 and docetaxol 30
mg/m2 d4 and d11, capecitabine
750 mg/m2 2 per day d1–d14 and
then 5-FU 225 mg/m2 with IMRT
IMRT 50 Gy to gross
disease, 45 Gy to
microscopic disease
64% 22% 15.64
mo(s)/—/—
89%
Stokes
et al. 51
2011 40 Borderline Capecitabine 1 g in morning, 2 g in
evening with radiotherapy
50.4 Gy 40% 58% 12 mo(s)/23
mo(s)/—
25%/44%/13%
(13 mo(s))
88%
Abbreviations: 5-FU, 5-fluorouracil; All/R/UR, all/resected/unresected; d, day(s); Gem, gemcitabine; Gy, gray; IMRT,
intensity-modulated radiation therapy; mo(s), month(s); Pts, patients; wk(s), week(s); yr(s), year(s).
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of effective chemotherapeutic or targeted agents probably ex-
plains the relatively modest improvement in survival from cur-
rent neoadjuvant or adjuvant trials. In the two gemcitabine-
based studies published by MDACC, about 60% of resected
patients eventually developed recurrence at distal organs at a
median time of only 8–13 months [26, 27]. Nonetheless, neo-
adjuvant therapy clearly provides a way to select for patients
who would benefit most from curative resection. On the other
hand, patients who have rapidly progressing disease during
neoadjuvant treatment can be spared from unnecessary sur-
gery. Recently FOLFIRINOX (oxaliplatin, irinotecan, leuco-
vorin, and 5-FU) was shown to be superior to gemcitabine in
patients with metastatic pancreatic cancer, with a median OS
of 11.1 months in the FOLFIRINOX group versus 6.8 months
in the gemcitabine group (p  .001) and a median progression-
free survival of 6.4 months versus 3.3 months (p  .001), al-
though FOLFIRINOX resulted in higher toxicity [28].
Although highly speculative, it is possible that neoadjuvant
FOLFIRINOX could improve the surgical outcome in selected
patients with good performance status.
WHAT IS ON THE HORIZON?
Cancer treatment has entered a molecular era. A targeted ap-
proach to therapy holds promise in many cancers due to its tol-
erability and high efficacy in specific patient populations. In
patients with locally advanced or metastatic pancreatic cancer,
gemcitabine plus an epidermal growth factor receptor inhibi-
tor, erlotinib, results in a modest but statistically significant
improvement in median OS (6.2 months versus 5.9 months,
hazard ratio p  .038) and progression-free survival (3.75
months versus 3.55 months, p  .004) when compared to treat-
ment with gemcitabine alone [29]. However, no further benefit
is found with addition of bevacizumab to the gemcitabine/
erlotinib combination [30, 31]. For patients with advanced
pancreatic cancer, combined use of gemcitabine and other tar-
geted agents such as bevacizumab [32], cetuximab [33], or
both [34] and axitinib [31] are not superior to gemcitabine
alone. Disappointing results from targeted therapies in pancre-
atic cancer have not necessarily discouraged researchers in the
field of pancreatic cancer but rather inspired them to investi-
gate other molecular targets that may be pertinent to tumori-
genesis, such as PI3K, Hedgehog, metalloproteinases, and
others [35]. Currently a phase II, multicentered trial by the
American College of Surgeons Oncology Group (ACOSOG-
Z5041) is ongoing to study the benefit of neoadjuvant or adju-
vant use of gemcitabine plus erlotinib in patients with
resectable pancreatic cancer. Another phase II trial
(NCT00460174) aims to study the effect of neoadjuvant gem-
citabine, bevacizumab, and radiation. On the basis of the prom-
ising outcome in metastatic pancreatic cancer, discussion on
FOLFORINOX as neoadjuvant therapy is being entertained by
academic oncologists [28]; however, the treatment-related tox-
icities have posed a challenge to incorporate this treatment into
the neoadjuvant setting.
Furthermore, new areas of targeted therapies are being ex-
plored for pancreatic cancer, which include modulating the tu-
mor microenvironment, improving drug delivery, augmenting
antitumor immunity, and targeting tumor stem cells. It is now
increasingly acknowledged that chemoresistance in pancreatic
cancer is greatly ascribed to the presence of a protective des-
moplastic, hypovascular stroma around the tumor, and this is
primarily driven by paracrine Hedgehog signaling from the tu-
mor cells to the microenvironment. Treatment with IPI-926, a
small-molecule inhibitor of the Sonic-Hedgehog pathway, im-
pairs proliferation of stromal myofibroblasts, inproves local
vasculature, and greatly improves delivery of gemcitabine to
the tumor in a murine model [36]. In another study, combined
use of gemcitabine and a CD40 agonist, which augments the
tumoricidal activity of T cells, resulted in favorable clinical re-
sponse in a small number of patients compared to historical
data using gemcitabine alone [37].
Improved delivery of radiotherapy such as intensity-mod-
ulated radiation therapy (IMRT) has the advantages of mini-
mizing toxicity, allowing higher doses of concurrent
chemotherapy, and reducing postoperative complications. A
phase II trial has recently been initiated at the University of
Michigan using IMRT with active breathing control and target
motion management to deliver a high-dose radiation, 50 Gy
Table 5. Surgical complications of pancreatoduodenectomy after neoadjuvant therapy
Patients undergoing
pancreatoduodenectomy
Delay in
surgery
>8 weeks
Perioperative
mortality, n
Major
complications,a
n (%)
Pancreatic
leaks, n
Bile
leaks,
n
Intra-abdominal fluid
collections requiring
intervention, n
Intraoperative
blood loss
(mL)
Median
hospital
stay
(days)
Breslin et al.
2001 13
132 2 1,281 13
Evans et al.
2008 27
64 10 (16%) 1 6 (9%) 1 1 2
Varadhachary
et al. 2008 26
52 8 (15%) 0 5 (9.6%) 0 1 0 675 10
Heinrich et al.
2008 10
24 0 1 736 16
aMajor complication: defined as grade III or higher based on validated classification system of surgical complications.
Grades I and II complications describe minor deviations from a normal postoperative course while grade III complications
require intervention under local (IIIA) or general (IIIB) anesthesia. Grade IV complications require ICU management while
grade V implies death of the patient 52, 53.
Abbreviations: n, number of patients.
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in 25 fractions, with concurrent full-dose gemcitabine,
1,000 mg/m2. Patients will undergo six cycles of induction
FOLFIRINOX, followed by concurrent chemoradiation and
two additional cycles of gemcitabine. After completion of neo-
adjuvant therapy, patients will be assessed for potential surgi-
cal resection. The utilization of IMRT limits the significant
toxicity associated with full-dose gemcitabine with concurrent
radiation and has previously been evaluated in an almost com-
pleted phase I/II trial in patients with localized unresectable
disease at the University of Michigan.
Though immature at this point, novel diagnostics such as
detection of circulating tumor cells and gene expression pro-
filing of tumor samples may allow stratification of patients
based on the risks of metastasis and invasion, which could po-
tentially help identify patients who most likely would benefit
from neoadjuvant therapies or upfront surgery.
THE FUTURE FOR THE NEOADJUVANT APPROACH
Resectable pancreatic cancer represents only about 15%–20%
of patients at the time of initial diagnosis, and it is clear that
surgical resection alone is inadequate. Development of more
effective chemotherapeutic or targeted agents is obviously the
key to truly improve the prognosis of this disease. Meanwhile,
many neoadjuvant studies incorporating new targeted agents
are ongoing, and the results will continue to impact future prac-
tice. Therefore, patients with resectable or borderline resect-
able pancreatic cancer should be encouraged to enroll in
clinical trials. In parallel, refinement of radiographic tech-
niques and standardization of imaging criteria on localized dis-
ease before and after neoadjuvant therapy will be essential to
better define truly operable candidates.
At this point in time, the major benefit of the neoadjuvant
approach, once more effective regimens are available, is that it
will allow downstaging of borderline resectable disease, and
perhaps a small subset of locally advanced pancreatic cancer
cases, to improve R0 resection and survival [21, 38].
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